** Shares of Australian Clinical Labs ACL.AX fall 18.9% to A$3, their lowest level since August 30, 2024
** Pathology services provider posts HY underlying NPAT of A$12.1 million ($7.68 million), below Visible Alpha consensus of A$15.5 million
** Co say it's on track to deliver FY25 underlying EBIT guidance in range of A$65 million to A$73 million, mid-point of which is lower than Visible Alpha consensus of A$71 million
** 1.1 million shares change hands, 2.1x the 30-day average of 527,734
** Stock down 12.8% YTD, including session's moves
($1 = 1.5748 Australian dollars)
(Reporting by Jasmeen Ara Shaikh in Bengaluru)
((Jasmeenaraislam.shaikh@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。